AGT and COVID-19: Pathogenic mechanisms suggesting that RASi could have a potentially harmful effect on COVID-19 progression are based on the observation that high levels of angiotensin II (Ang II) were observed in COVID-19 patients and correlated with lung injury, supporting RAS activation during SARS-CoV-2 infection [18].